Loading...
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
BACKGROUND: Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patients with resistant EGFR-mutant lung cancer. ME...
Saved in:
| Published in: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group UK
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6474279/ https://ncbi.nlm.nih.gov/pubmed/30880334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0428-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|